CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 5 enrolled
Drug / intervention
ranibizumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00456495
NCT00456495Phase 1Completed
CompareCT.gov

Effect of Ranibizumab on Malignant Conjunctival Neoplasia

The New York Eye Cancer Center·interventional·Posted Apr 5, 2007·Updated Jul 21, 2017

In Brief

A Phase 1 clinical trial evaluating ranibizumab for Conjunctival Neoplasms. Completed, enrolled 5 participants across 1 site.

Detailed Summary

The purpose of this study is to test the safety and tolerability of subconjunctival injection of ranibizumab in the treatment of malignant conjunctival neoplasia using the incidence and severity of adverse events. Our secondary objective is to assess the efficacy of ranibizumab treatment on malignant conjunctival neoplasia by evaluating tumor destruction or reduction as documented by slit-lamp photography and ultrasonographic imaging and the regression of blood vessels.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsConjunctival Neoplasms
CountriesUnited States
CollaboratorsGenentech, Inc.

Timeline

Phase 1CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 5, 2007
Enrollment StartMar 1, 2007
Primary CompletionSep 1, 2010
TodayJul 2, 2026
Enrollment to primary: 3.5 yearsPosted 19.2 years ago

Interventions

ranibizumabdrug

Subconjunctival injection of drug every 2 to 4 weeks